Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announced that Kim Kelderman, President and CEO, will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:00 a.m. PST. A live webcast will be available via the company's Investor Relations Calendar page.
Investors can access the presentation through the IR Calendar on Bio-Techne's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – TECH
In the Dec 23 session, TECH gained 0.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Strategic partnership | Positive | -0.9% | Collaboration to develop automated 3D multiomic spatial biology workflow. |
| Dec 09 | Product launch | Positive | -2.4% | Launch of enhanced Leo System for higher-throughput multiplex protein analysis. |
| Nov 25 | Investor conferences | Neutral | +3.7% | Announcement of three upcoming investor conference presentations in early December. |
| Nov 18 | AI licensing deal | Positive | -0.8% | Licensing of AI-designed NovoBody Duo molecules to expand protein portfolio. |
| Nov 06 | Investor conferences | Neutral | -2.9% | Scheduling of four November healthcare investor conference presentations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent product, partnership, and AI licensing news with generally positive business tone have been followed by modest negative next-day price moves, while generic conference announcements showed mixed reactions.
Over the last two months, Bio‑Techne reported several business updates, including a Wyss Center collaboration to extend 3D multiomics (Dec 11, 2025), the enhanced Leo System launch with higher multiplexing (Dec 9, 2025), and an AI‑designed NovoBody™ Duo licensing deal (Nov 18, 2025). It also announced multiple investor conference presentations in November and late November. Those prior conference notices provide context for the new J.P. Morgan Healthcare Conference appearance as part of an ongoing investor outreach cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Contact: | David Clair, Vice President, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-2026-jp-morgan-healthcare-conference-302648108.html
SOURCE Bio-Techne Corporation